AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29442086 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation at 50 Hz for 3 min after the endodontic procedure (Group B)
Number of subjects: 120
Study 29442086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen and low-level laser therapy (Group C)
Number of subjects: 120
Study 29442086 — intervention group
Group type: COMPARATOR
Intervention: No preoperative ibuprofen nor low-level laser irradiation (Group D)
Number of subjects: 120
Study 26968380 — intervention group
Group type: COMPARATOR
Intervention: Moderate hyperoxia (PaO2 target of 200-220 mmHg during cardiopulmonary bypass and 130-150 mmHg during ICU admission)
Number of subjects: 50
Study 26968380 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-physiological oxygen strategy (PaO2 target of 130-150 mmHg during cardiopulmonary bypass and 80-100 mmHg during ICU admission)
Number of subjects: 50
Study 24012063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and enema mesalazine (4 g/day oral + 1 g enema)
Number of subjects: 0
Study 24012063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and enema mesalazine
Number of subjects: 0
Study 24012063 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalazine (4 g/day)
Number of subjects: 0
Study 22311905 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg)
Number of subjects: 135
Study 22311905 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated aspirin
Number of subjects: 135
Study 22311905 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release aspirin
Number of subjects: 135
Study 20696865 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 451
Study 20696865 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 451
Study 18715213 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin guidance software (ACCU‐CHEK Advisor)
Number of subjects: 123
Study 18715213 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 15761191 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib (120 mg QD)
Number of subjects: 19
Study 15761191 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib (120 mg BID)
Number of subjects: 19
Study 15761191 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 19
Study 12454555 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75 to 225 mg/day)
Number of subjects: 0
Study 12454555 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (37.5 mg, 75 mg, or 150 mg, fixed-dose)
Number of subjects: 0
Study 12454555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10622338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast rTMS (10 Hz)
Number of subjects: 18
Study 10622338 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow rTMS (0.3 Hz)
Number of subjects: 18
Study 10622338 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 8717568 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine delivered by wound catheter
Number of subjects: 70
Study 8717568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 70
Study 1673944 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 10 mg BID
Number of subjects: 36
Study 1673944 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens alone
Number of subjects: 36
Study 1673944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (medroxyprogesterone acetate and conjugated estrogens)
Number of subjects: 36
Study 6108592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (4 or 5 mg)
Number of subjects: 8
Study 6108592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (1 or 2 mg)
Number of subjects: 8
Study 6108592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6108592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (comparatively lower doses)
Number of subjects: 8
Study 31940784 — intervention group
Group type: EXPERIMENTAL
Intervention: DYNAMAP system for noise monitoring
Number of subjects: 21
Study 31940784 — intervention group
Group type: COMPARATOR
Intervention: Field measurements of noise levels
Number of subjects: 21
Study 31136050 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally hydroformed reconstruction plate
Number of subjects: 12
Study 31136050 — intervention group
Group type: COMPARATOR
Intervention: Manually prebent reconstruction plate
Number of subjects: 12
Study 28911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasping during CPR
Number of subjects: 1827
Study 28911510 — intervention group
Group type: COMPARATOR
Intervention: No gasping during CPR (Control)
Number of subjects: 1827
Study 28911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasping combined with shockable initial recorded rhythm
Number of subjects: 1827
Study 28911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1827
Study 28911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockable initial recorded rhythm
Number of subjects: 1827
Study 28911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter CPR duration
Number of subjects: 1827
Study 28911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower epinephrine dosage
Number of subjects: 1827
Study 28911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary edema
Number of subjects: 1827
Study 26285325 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory and relaxation training
Number of subjects: 62
Study 23959833 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677 TT genotype
Number of subjects: 600
Study 23959833 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR T allele
Number of subjects: 600
Study 23959833 — intervention group
Group type: EXPERIMENTAL
Intervention: MTRR 66 GG
Number of subjects: 600
Study 20852441 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone
Number of subjects: 28
Study 20852441 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 28
Study 20852441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 28
Study 19584831 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2b alone (100 microg per week)
Number of subjects: 172
Study 19584831 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2b and lamivudine (100 mg/day)
Number of subjects: 172
Study 19584831 — intervention group
Group type: COMPARATOR
Intervention: HBeAg loss within 32 weeks
Number of subjects: 172
Study 19584831 — intervention group
Group type: COMPARATOR
Intervention: HBeAg loss after week 32
Number of subjects: 172
Study 17426158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg)
Number of subjects: 111
Study 17426158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (25 mg/kg of the sulfadoxine component)
Number of subjects: 111
Study 15198277 — intervention group
Group type: EXPERIMENTAL
Intervention: zaleplon 10 mg
Number of subjects: 23
Study 15198277 — intervention group
Group type: EXPERIMENTAL
Intervention: zopiclone 7.5 mg
Number of subjects: 23
Study 15198277 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam 15 mg
Number of subjects: 23
Study 15198277 — intervention group
Group type: EXPERIMENTAL
Intervention: time‐released melatonin 6 mg
Number of subjects: 23
Study 15198277 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 11351356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (50 mg x 3/day for 2 months)
Number of subjects: 40
Study 11351356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9437195 — intervention group
Group type: COMPARATOR
Intervention: Alpha-tocopherol (50 mg daily)
Number of subjects: 26289
Study 9437195 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene (20 mg daily)
Number of subjects: 26289
Study 9437195 — intervention group
Group type: COMPARATOR
Intervention: Alpha-tocopherol and beta-carotene (50 mg and 20 mg daily respectively)
Number of subjects: 26289
Study 9437195 — intervention group
Group type: COMPARATOR
Intervention: No alpha-tocopherol
Number of subjects: 26289
Study 9437195 — intervention group
Group type: COMPARATOR
Intervention: No beta-carotene
Number of subjects: 26289
Study 7893581 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 20
Study 3287167 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg per day, five days per week)
Number of subjects: 100
Study 3287167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3287167 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 100
Study 30626196 — intervention group
Group type: EXPERIMENTAL
Intervention: BattleViro (ART-related iPhone game)
Number of subjects: 61
Study 30626196 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-related game (Control)
Number of subjects: 61
Study 27330807 — intervention group
Group type: EXPERIMENTAL
Intervention: CVac maintenance treatment (10 doses over 56 weeks)
Number of subjects: 56
Study 27330807 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) observation
Number of subjects: 56
Study 25792354 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance through an impedance threshold device (ITD)
Number of subjects: 26
Study 25792354 — intervention group
Group type: COMPARATOR
Intervention: Sham device (no resistance)
Number of subjects: 26
Study 23096417 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote programming using a remote-presence robot (RP-7) with expert telementoring of nonexpert nurses.
Number of subjects: 20
Study 23096417 — intervention group
Group type: COMPARATOR
Intervention: Conventional programming sessions.
Number of subjects: 20
Study 20943270 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse in women
Number of subjects: 2782
Study 20943270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse in women
Number of subjects: 2782
Study 20943270 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical punishment in women
Number of subjects: 2782
Study 20943270 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional neglect in women
Number of subjects: 2782
Study 20943270 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional neglect in men
Number of subjects: 2782
Study 20943270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse in men
Number of subjects: 2782
Study 18300236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg orally twice daily and bevacizumab 5 mg/kg to 10 mg/kg intravenously every 2 weeks for 28-day cycles
Number of subjects: 15
Study 18300236 — intervention group
Group type: COMPARATOR
Intervention: CA125 criteria
Number of subjects: 15
Study 18300236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined imaging and CA125 criteria
Number of subjects: 15
Study 16614544 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (1 week placebo lead-in)
Number of subjects: 0
Study 12796772 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (4 x 10(9) particle units)
Number of subjects: 105
Study 12796772 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (4 x 10(10) particle units)
Number of subjects: 105
Study 12796772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 11195956 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) combined with Medroxyprogesterone acetate (MPA)
Number of subjects: 81
Study 11195956 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V-CPA (estradiol valerate combined with cyproterone acetate)
Number of subjects: 81
Study 8866624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepyramine (0.5 mg.kg‐1) pretreatment
Number of subjects: 7
Study 8866624 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 7
Study 1346499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and plasma exchange (group A)
Number of subjects: 78
Study 1346499 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (group B)
Number of subjects: 78
Study 1346499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide or dapsone therapy (as second-line treatment)
Number of subjects: 78
Study 6376164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg curantyl
Number of subjects: 55
Study 6376164 — intervention group
Group type: COMPARATOR
Intervention: 40 mg no-spa
Number of subjects: 55
Study 31109200 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (36 or 54 mg/day of extended-release)
Number of subjects: 94
Study 31109200 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gradual withdrawal over 3 weeks)
Number of subjects: 94
Study 31109200 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (continuation group)
Number of subjects: 94
Study 31109200 — intervention group
Group type: COMPARATOR
Intervention: Placebo (discontinuation group)
Number of subjects: 94
Study 28739058 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bead patch (N=57)
Number of subjects: 110
Study 28739058 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure patch (N=53)
Number of subjects: 110
Study 25643863 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg Engerix-B
Number of subjects: 319
Study 25643863 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg Engerix-B
Number of subjects: 319
Study 25643863 — intervention group
Group type: COMPARATOR
Intervention: Non-zero anti-HBs levels (Group 2)
Number of subjects: 319
Study 25643863 — intervention group
Group type: COMPARATOR
Intervention: Non-zero anti-HBs levels (Group 3)
Number of subjects: 319
Study 24094079 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose statin
Number of subjects: 109
Study 24094079 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe-plus-statin
Number of subjects: 109
Study 21591571 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD intervention in patients with ischaemic heart disease (IHD)
Number of subjects: 101
Study 21591571 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD intervention in patients with idiopathic dilated cardiomyopathy (IDCM)
Number of subjects: 101
Study 21591571 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 101
Study 21591571 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 101
Study 21591571 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF < 25% vs 25-34%
Number of subjects: 101
Study 21591571 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration
Number of subjects: 101
Study 21591571 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class
Number of subjects: 101
Study 21591571 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive EPS
Number of subjects: 101
Study 19155060 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 180
Study 19155060 — intervention group
Group type: COMPARATOR
Intervention: Open pyloromyotomy
Number of subjects: 180
Study 19155060 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study 19482814 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone exercise counseling (n = 39)
Number of subjects: 81
Study 19482814 — intervention group
Group type: COMPARATOR
Intervention: Combined control groups (n = 42)
Number of subjects: 81
Study 19482814 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail participants (n = not specified)
Number of subjects: 81
Study 19482814 — intervention group
Group type: EXPERIMENTAL
Intervention: Not frail group (n = not specified)
Number of subjects: 81
Study 15091267 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nail
Number of subjects: 45
Study 15091267 — intervention group
Group type: COMPARATOR
Intervention: Unreamed nail
Number of subjects: 45
Study 9786811 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy alone
Number of subjects: 450
Study 9786811 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine plus prednisone (3-month course, initial dosage 0.4 to 0.5 mg/kg/day)
Number of subjects: 450
Study 9786811 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral prednisone (80 to 100 mg/d for 6 months) and orbital radiation therapy (20 Gy per eye over 2 weeks)
Number of subjects: 450
Study 7840401 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 7840401 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study 3146774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg o.d. in the morning)
Number of subjects: 0
Study 3146774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30700565 — intervention group
Group type: EXPERIMENTAL
Intervention: Device feedback (DF) group (n = 223)
Number of subjects: 653
Study 30700565 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor and device feedback (IDF) group (n = 205)
Number of subjects: 653
Study 30700565 — intervention group
Group type: EXPERIMENTAL
Intervention: Device feedback (DF) group
Number of subjects: 653
Study 30700565 — intervention group
Group type: COMPARATOR
Intervention: Instructor feedback (IF) group
Number of subjects: 653
Study 27170277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-mini percutaneous nephrolithotomy (UPNL)
Number of subjects: 97
Study 27170277 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (SPNL)
Number of subjects: 97
Study 26738059 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone users
Number of subjects: 0
Study 26738059 — intervention group
Group type: COMPARATOR
Intervention: Paper diary users
Number of subjects: 0
Study 22884532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein enteral diet enriched with ginger
Number of subjects: 32
Study 22884532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21481414 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 54
Study 21481414 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 54
Study 18277840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberglass volar slab
Number of subjects: 84
Study 18277840 — intervention group
Group type: COMPARATOR
Intervention: Encircling plaster-of-paris cast
Number of subjects: 84
Study 18277840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 16794988 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 69
Study 16794988 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal anxiety at 12 and 36 months
Number of subjects: 69
Study 16794988 — intervention group
Group type: COMPARATOR
Intervention: Full-term infants
Number of subjects: 69
Study 14738167 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet form of misoprostol (400 microg)
Number of subjects: 27
Study 14738167 — intervention group
Group type: COMPARATOR
Intervention: Capsule form of misoprostol (400 microg)
Number of subjects: 27
Study 10866895 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine 2% with hyaluronidase
Number of subjects: 60
Study 10866895 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 2%-bupivacaine 0.5% mixture with hyaluronidase
Number of subjects: 60
Study 9339095 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of intravaginal misoprostol
Number of subjects: 50
Study 9339095 — intervention group
Group type: COMPARATOR
Intervention: 3 mg of dinoprostone
Number of subjects: 50
Study 7692109 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone (2 gm.)
Number of subjects: 599
Study 7692109 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160/800 mg.)
Number of subjects: 599
Study 7692109 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial prophylaxis
Number of subjects: 599
Study 2877569 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 100
Study 2877569 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 100
Study 30267399 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP
Number of subjects: 50
Study 30267399 — intervention group
Group type: COMPARATOR
Intervention: 177Lu-EDTMP
Number of subjects: 50
Study 26223004 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercises
Number of subjects: 90
Study 26223004 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobics exercises
Number of subjects: 90
Study 26223004 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 25570941 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 21
Study 25570941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23214304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Polis DX toothpaste with propolis content (T)
Number of subjects: 80
Study 23214304 — intervention group
Group type: EXPERIMENTAL
Intervention: Carepolis gel with propolis content (CT)
Number of subjects: 80
Study 23214304 — intervention group
Group type: COMPARATOR
Intervention: Dental Polis DX toothpaste without propolis content (G)
Number of subjects: 80
Study 23214304 — intervention group
Group type: COMPARATOR
Intervention: Carepolis gel without propolis content (CG)
Number of subjects: 80
Study 20015704 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream (0.075%) applied to the C(5) dermatome
Number of subjects: 40
Study 20015704 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo cream applied to the C(5) dermatome
Number of subjects: 40
Study 18550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language version of the World Mental Health Survey Composite International Diagnostic Interview
Number of subjects: 332
Study 18550562 — intervention group
Group type: COMPARATOR
Intervention: English-language version of the World Mental Health Survey Composite International Diagnostic Interview
Number of subjects: 332
Study 15938534 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10 mg daily, increased to 20 mg)
Number of subjects: 96
Study 15938534 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (25 mg twice a day, increased to 75 mg)
Number of subjects: 96